Stocks to Watch: Gemini Explorations, Inc. (OTCBB: GXPI), CV Therapeutics, Inc. (NasdaqGM:CVTX) , Spicy Pickle (OTC BB:SPKL) , Emergent Biosolutions Inc. (NYSE:EBS), DIRT Motor Sports, Inc. (OTC BB:DMSP)
Featured Stock: Gemini Explorations, Inc.
(OTCBB: GXPI)
Current Price (0.08)
Francis Gaskins of IPOdesktop Releases Analyst Report on Gemini Explorations Inc.
Monday October 1, 5:47 am ET
CALGARY, AB-- Oct 1, 2007 -- Gemini Explorations Inc. (OTC BB:GXPI.OB - News), an emerging gold mining company focused on the development of two highly prospective gold projects in Colombia, announced today that it has been issued an intermediate price target. Francis Gaskins at IPOdesktop initiated coverage on the company.
|
|
Recently, Gemini released an updated overview of its wholly owned La Planada Gold Project as prepared by Carlos Alberto Vera, Chief Geologist of Minera Primecap Geological Services. The detailed update estimates a potential deposit of 3,150,000 troy ounces of gold or a gross deposit value of approximately $2,310,000,000 with gold presently trading at $735 per ounce are possible from the La Planada Project.
Francis Gaskins ... the Internet's most Experienced Interviewer
Francis Gaskins, a seasoned financial analyst, is noted as the Internet's most experienced, analytical web cast producer and interviewer. Often quoted, his scope of influence includes editor (IPOdesktop), Talk Radio, Internet TV, and Video Productions, plus numerous articles and opinions published in the nation's financial media.
IPOdesktop Editor
-- The leading provider of independent IPO research for professional money managers and individual investors.-- One of 'Forbes Best IPO Sites.'-- Widely quoted by the IPO media including the Wall Street Journal, Dow Jones Business News, Dow Jones Newswires, Reuters, USA TheStreet.com, and CBS MarketWatch.
National Media Exposure
-- IPOdesktop editors are quoted by The Wall Street Journal, Dow Jones Newswires, MarketWatch, Reuters, USATODAY, and others. IPO Hardball! the weekly podcast, is hosted by Gaskins at Streetiq.com-- Gaskins himself often appears as a guest IPO commentator for CNBC and Bloomberg Television.
Internet Radio
-- Co-host for the weekly IPO Hardball! Internet radio show, also broadcast from CBS Marketwatch.-- Business & financial talk show host at WorldTalkRadio.
Education & Experience
-- Harvard University -- Princeton University
Seasoned team leader: extensive experience in sales, marketing, pre-IPO financial analysis and valuations, fund raising, forecasting and budgeting, strategic modeling, general ledger and preparation of financial statements, market research.
Internet Television
-- Packages virtual road shows.
What clients say...
-- "Bravo -- you do a wonderful job, btw -- this went extremely well."-- "Great interview!"-- "Our distributor in the UK -- "Thank you very much, Francis. I really enjoy working with you."-- "We really appreciate the work you put into making these interviews very informative and worthwhile."-- "I love the interview. This (concise, summary) information is hardly ever made known to the public."-- "It's a privilege working with a professional and empathetic gentleman like you. I enjoy the experience and greatly appreciate your help. All the best!"-- "The interview is timely and well done. Kudos!"
To reach the full analyst research report, please visit: http://www.gaskinsco.com/linkto-gxpi.shtml
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, that although Gemini Explorations, Inc believes the La Planada Gold Project has promising potential, the property is in the early stages of exploration. The project has yet to be shown to contain proven or probable mineral reserves. There can be no assurance that such reserves will be identified on the property, or that, if identified, mineralization may be economically extracted. Minera Primecap Geological Services does not accept responsibility for the use of project data or in the adequacy or accuracy of this release.
Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with mineral exploration. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-KSB for the 2005 fiscal year, our quarterly reports on Form 10-QSB and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact:
Michael Hill President Gemini Explorations, Inc. Suite 103240-11th Ave SW Calgary , AB T2R 0C3 http://www.geminiexploration.com email: info@geminiexploration.com IR info: 1 877 700 1644
Source: Gemini Explorations, Inc.
For an in-depth analyst report, please visit: www.WallstreetStockReview.com
CV Therapeutics, Inc.
(NasdaqGM:CVTX)
Current Price (8.98)
PALO ALTO, Calif., Sept. 27 -- CV Therapeutics, Inc. (Nasdaq: CVTX - News) announced today that the Company has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking an expansion to the approved product labeling for Ranexa® (ranolazine extended-release tablets). CV Therapeutics, Inc., headquartered in
Spicy Pickle
(OTC BB:SPKL)
Current Price (0.95)
DENVER, CO----Sep 27, 2007 -- Spicy Pickle® fast casual restaurants (OTC BB:SPKL.OB - News) today announced it has signed its first franchisee in the state of Florida.A new franchisee with restaurant experience in another concept has entered into a franchise agreement to open the first Spicy Pickle Restaurant in the Ocala/Gainesville region of central Florida. Founded in 1999, Spicy Pickle Franchising, Inc. (OTC BB:SPKL.OB - News) serves high quality meats and fine artisan breads, baked fresh daily, along with a wide choice of eight different cheeses, twenty-two different toppings, and fourteen proprietary spreads to create healthy and delicious panini and sub sandwiches with flavors from around the world. As a leading ``fast-casual'' concept, Spicy Pickle offers menu items that are far beyond traditional fast food -- but without the price point of casual dining. The hallmark of a Spicy Pickle restaurant is quality, service and an enjoyable atmosphere. The company is headquartered in
Emergent Biosolutions Inc.
(NYSE:EBS)
Current Price (8.94)
ROCKVILLE, Md.--Sept 27--Emergent BioSolutions Inc. (NYSE:EBS - News) announced today that it has received a development contract, valued at up to $9.5 million, in support of non-clinical and clinical studies of the company's anthrax therapeutic, or AIG, product candidate. This product candidate is an immune globulin being developed as an intravenous therapeutic for treatment of patients who present with symptoms of anthrax disease following exposure to anthrax. Emergent BioSolutions, Inc., a biopharmaceutical company, together with its subsidiaries, focuses on the development, manufacture, and commercialization of immunobiotics. Immunobiotics are pharmaceutical products, such as vaccines and immune globulins that assist the body?s immune system to prevent diseases. It has two segments, Biodefense and Commercial. The Biodefense segment develops and commercializes immunobiotics for use against biological agents, which are weapons of bioterrorism. This segment?s primary product includes BioThrax, a vaccine for the prevention of anthrax infection. Its other products, which are in preclinical stage comprise Anthrax Immune Globulin, for post-exposure treatment of anthrax infection; Recombinant Bivalent Botulinum Vaccine, a prophylaxis for botulinum; and Botulinum Immune Globulin for post-exposure treatment of botulinum intoxication. The Commercial segment develops immunobiotics for use against infectious diseases with unmet or underserved medical needs. This segment?s product portfolio consists of Typhoid Vaccine, a single-dose drinkable vaccine in phase II clinical trial; Hepatitis B Therapeutic Vaccine, for treating chronic carriers of hepatitis B infection, which has completed phase I clinical trial; Group B Streptococcus Vaccine in phase I clinical trial; Meningitis B Vaccine, a recombinant protein sub-unit vaccine for babies, children, and adolescents that has completed phase I clinical trial; and Chlamydia Vaccine, for the prevention of chlamydia trachomatis in preclinical stage. Emergent BioSolutions serves primarily the department of defense and the health and human services. It operates in the
DIRT Motor Sports, Inc.
(OTC BB:DMSP)
Current Price (0.52)
WallStreetStockReview.com is owned and operated by Iron Consulting.
Verify all claims and do your own due diligence. Iron Consulting profiles are not a solicitation or recommendation to buy, sell or hold securities. Iron Consulting is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Iron Consulting is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b),WallStreetStockReview.com is owned and operated by Iron Consulting. Iron Consulting www.ironconsultinginc.com has receive seventy two thousand dollars in 2006 and thirty six thousand in 2007 from Equity Alliance Intl. www.equityallianceir.com for a internet marketing program. Neither Iron Consulting nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Iron Consulting receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Iron Consulting statements and opinions and such statements and opinions cannot be considered independent. Iron Consulting and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements ar e made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Iron Consulting services are often paid for using free-trading shares. Iron Consulting may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
